In a post on the New York Times’ “Opinionator” blog, author and journalist Tina Rosenberg writes about the Medicines Patent Pool (MPP) and describes how it can help purchase AIDS drugs for “vast numbers of people.” She also notes “its most serious potential weakness” – that drug companies join because they hope that giving earlier drug access to more countries will reduce pressure for access in middle-income countries. Rosenberg highlights a recent agreement with Gilead Sciences, which “only covers very poor countries. It leaves out Egypt, China, Brazil, plus dozens of other developing countries. Current AIDS drug prices in these countries are six or seven times the price of drugs in sub-Saharan Africa. Without help from the patent pool, these countries have little hope of expanding antiretroviral coverage” (7/21).